Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Nicholas A. DeMonaco"'
Publikováno v:
Clinical Lymphoma and Myeloma. 7:369-372
A 75-year-old man with relapsed follicular non-Hodgkin lymphoma confined to a solitary lung mass was treated with radioimmunotherapy (RIT) using yttrium 90-ibritumomab tiuxetan. Imaging with positron emission tomography/computed tomography showed a c
Autor:
Anthony M. Harrison, Norbert Avril, Nicholas A. DeMonaco, N. Vidnovic, Samuel A. Jacobs, Judith M. Joyce, Kenneth A. Foon, Kenneth S. McCarty, Steven H. Swerdlow
Publikováno v:
Molecular imaging and biology. 11(1)
90Yttrium-ibritumomab-tiuxetan (Zevalin) is an effective treatment for relapsed or refractory low-grade, follicular, or transformed B-cell NHL. The purpose of this study is to assess whether tissue and cellular localization of 90Y-ibritumomab–tiuxe
Autor:
Samuel A. Jacobs, Nicholas A. DeMonaco
Publikováno v:
Clinical nuclear medicine. 32(12)
A previously healthy 47-year-old woman was treated for follicular lymphoma, grade III, with cyclophosphamide, adriamycin, vincristine, prednisone with rituximab (CHOP-R) followed by ibritumomab tiuxetan and rituximab. She developed a serum sickness-l
Publikováno v:
The American Journal of Medicine. 121:e19
Autor:
Samuel A. Jacobs, Terry Evans, Jennifer Osborn, Judith Joyce, Steven H. Swerdlow, Nicholas A. DeMonaco, Stephanie R. Land, The Minh Luong, Kenneth A. Foon, Rachel C. Jankowitz
Publikováno v:
Blood. 112:2001-2001
Sequential treatment with chemotherapy and radioimmunotherapy (RIT) results in overall response rates > 90% in untreated follicular lymphoma (FL). We previously reported a complete response rate (CR) of 89% in 60 patients with stage II–IV symptomat
Autor:
Stephanie R. Land, Nicholas A. DeMonaco, Steven H. Swerdlow, M. Wu, Kenneth A. Foon, Jennifer L. Osborn, Terry Evans, Rachel C. Jankowitz, Samuel A. Jacobs, Judith M. Joyce
Publikováno v:
Journal of Clinical Oncology. 25:8005-8005
8005 Background: Therapy with CHOP-R and radioimmunotherapy (RIT) is a promising treatment for untreated FL. Press reports complete responses (CR) of 69% in FL patients (pts.) with 6 cycles of CHOP followed by I-131 tositumomab. We report efficacy an
Autor:
Jeffrey A. Kant, Nicholas A. DeMonaco, Judith M. Joyce, Kenneth A. Foon, M. Wu, Stephanie R. Land, Steven H. Swerdlow, Terry Evans, Samuel A. Jacobs, Jennifer L. Osborn
Publikováno v:
Journal of Clinical Oncology. 24:7589-7589
7589 Background: There has been some question regarding the predictive value of 111In scans in FL. We report imaging results with fusion PET-CT scans and 111In scans in a single-institution, non-randomized, phase II trial in patients with FL treated
Autor:
Nicholas A. DeMonaco, Kenneth A. Foon, Stephanie R. Land, Jennifer L. Osborn, Michael Wu, Samuel A. Jacobs, Steven H. Swerdlow, Judith M. Joyce, Terry Evans, Jeffrey A. Kant
Publikováno v:
Blood. 106:2449-2449
Background: CHOP-rituximab (CHOP-R) and radioimmunotherapy (RIT) have demonstrated efficacy in the treatment of follicular NHL. The combination of these agents as initial therapy is a novel strategy which has been previously reported with promising r
Publikováno v:
Blood. 106:586-586
Pulmonary embolism (PE) is a major cause of morbidity in hospitalized patients, yet few data exist on PE incidence and characteristics among hospitalized patients. If those at greatest risk were able to be identified, early prevention might improve h
Autor:
Daniel A. Judelson, William J. Kraemer, Carl M. Maresh, Barry A. Spiering, Jeff S. Volek, Jason D. Vescovi, Ricardo Silvestre, Wesley C. Hymer, Nicholas A. Demonaco
Publikováno v:
Medicine & Science in Sports & Exercise. 36:S302